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Introduction
Alternative splicing of RNA is a key mechanism in increasing 
complexity of mRNA and protein metabolism. Imbalances 
in this splicing process may thus affect the progression of 
various human diseases. Identifying compounds capable 
of modulating this imbalance therefore provides new and 
interesting therapeutic perspectives.1 Splicing is a con-
served mechanism controlled by the spliceosome, a com-
plex composed of five small nuclear RNAs (U1, U2, U4, U5, 
and U6) that assemble with proteins to form small nuclear 
ribonucleoproteins (snRNPs).2 The production of alterna-
tively spliced mRNAs is regulated by a system of trans-
acting proteins that bind to cis-acting sites on the primary 
transcript itself. Each of these RNA-binding proteins has 
quite widespread effects on a number of genes. This sheds 
doubt on the ability of chemical compounds to target these 
factors in such a way as to have beneficial effects, without 
inducing concomitant deleterious consequences. One way 
to address this potential problem would be to focus on the 
repositioning of FDA-approved compounds that may affect 
alternative RNA splicing. It has already been demonstrated 
that marketed drugs such as clotrimazole, flunarizine, digi-
toxin, pentamidine, and manumycin A can also affect the 
alternative splicing machinery, raising the exciting pros-
pect that the efficacy of disease-specific therapies may be 
enhanced by medications that target alternative splicing 
machinery.3–6
Within this framework, we were interested in the hypoth-
esis that metformin, one of the most commonly prescribed 
antidiabetic drugs, downregulates the expression of a small 
subset of ribonucleic acid-binding proteins.7 The effect of 
metformin on splicing machinery was explored in the patho-
logical context of myotonic dystrophy type 1 (DM1), a model 
of spliceopathy where metformin is used to treat insulin 
resistance in DM1 patients.1,8 DM1 is characterized by a 
defect in the alternative RNA splicing machinery, where 80% 
of the splicing alterations are related to the nuclear seques-
tration of the RNA-binding protein MBNL1 on myotonin pro-
tein kinase gene (DMPK) transcripts containing an abnormal 
expansion of CUG repeats in the 3′ UTR.9–14 These nuclear 
aggregates also promote CELF1 hyperactivation,15 and the 
concomitant deregulation of these two splicing factors pro-
motes the alteration of alternative splicing in various genes 
that have been linked to symptoms of DM1.16–18
We therefore explored the consequences of metformin 
application with DM1-related abnormalities in alternative 
RNA splicing, using an in vitro model based on a human 
embryonic stem cell line (hESC) derived from an embryo 
characterized as a DM1-gene carrier during a preimplan-
tation genetic diagnosis. This cell line was already instru-
mental in revealing alterations of the expression of several 
genes associated with functional disturbances in DM1.19–21 
Our results confirmed the ability of metformin to modify 
alternative splicing events, including some that are defec-
tive in DM1.
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Major physiological changes are governed by alternative splicing of RNA, and its misregulation may lead to specific diseases. With 
the use of a genome-wide approach, we show here that this splicing step can be modified by medication and demonstrate the effects 
of the biguanide metformin, on alternative splicing. The mechanism of action involves AMPK activation and downregulation of the 
RBM3 RNA-binding protein. The effects of metformin treatment were tested on myotonic dystrophy type I (DM1), a multisystemic 
disease considered to be a spliceopathy. We show that this drug promotes a corrective effect on several splicing defects associated 
with DM1 in derivatives of human embryonic stem cells carrying the causal mutation of DM1 as well as in primary myoblasts 
derived from patients. The biological effects of metformin were shown to be compatible with typical therapeutic dosages in a clinical 
investigation involving diabetic patients. The drug appears to act as a modifier of alternative splicing of a subset of genes and may 
therefore have novel therapeutic potential for many more diseases besides those directly linked to defective alternative splicing.
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Results
Effects of metformin treatment on RNA-binding protein 
expression
The downregulation of transcripts encoding five ribonucleic acid-
binding proteins (RBM3, SRSF1, SFPQ, SRSF6, and RBM45) 
by metformin in the millimolar range was identified by Larsson 
et al.7 Concordant with this study, we confirmed that metformin 
induced a statistically significant decrease of RBM3 in DM1 and 
wild-type mesodermal precursor cells (MPCs) differentiated from 
DM1 and control hESCs at a dose of 25 mmol/l (Figure 1 and 
Supplementary Figure S1a). In contrast, metformin treatment 
did not result in a statistically significant alteration of expres-
sion of SRSF1, SFPQ, SRSF6, and RBM45  (Supplementary 
 Figure S1b) or MBNL122 and CELF1, both of which are involved 
in the pathological mechanisms of DM1 (Figure 1).
The effect of metformin treatment on cell viability, toxicity, 
apoptosis, and proliferation was monitored in DM1 MPCs 
exposed to a range of metformin doses. Treatments with 
the drug for 48 hours did not affect viability, cytotoxicity, or 
apoptosis up to doses of 35 mmol/l. Treatments for 24 hours 
with increasing doses of ionomycin and staurosporine, used 
as positive controls, induced as expected a rapid increase 
Figure 1 Metformin treatment modulates expression of the RBM3 RNA-binding protein. Western blot analysis of myotonic dystrophy 
type I mesodermal precursor cells treated for 48 hours with different doses of metformin demonstrated selective downregulation of RBM3, 
but not of CELF1 and MBNL1. Data (mean + SD) were analyzed with analysis of variance and the Steel-Dwass all pairs post hoc test. 
***P < 0.001.
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Figure 2 Effect of metformin treatment on myotonic dystrophy type I (DM1) mesodermal precursor cell (MPC) proliferation, apoptosis, 
and cytotoxicity. (a) DM1 MPCs were incubated with vehicle or increasing concentrations of metformin for 48 hours or staurosporine and 
ionomycin for 24 hours before measurement of viability, apoptosis, and toxicity with the ApoTox reagent. (b,c) DM1-mutated MPCs were 
treated with a range of metformin doses. Total cell numbers were determined at 0, 24, and 48 hours. Percentage of cells expressing the Ki-67 
proliferation marker was analyzed after 48 hours of treatment. NT, not treated; RFU, relative fluorescence unit; RLU, relative luminescence unit.
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of cytotoxicity and apoptosis, respectively23,24 (Figure 2a–c). 
Proliferation analysis of DM1 MPCs showed that metformin 
treatment tended to promote a cytostatic effect at a dose of 
10 mmol/l, with a greater effect at 25 mmol/l (Figure 2b). This 
was correlated with a progressive decrease in the number of 
cells expressing the Ki-67 proliferation marker (Figure 2c).
Effects of metformin on DM1-associated splicing defects
The consequences of metformin treatment were next analyzed 
on DM1-associated splicing defects in MPCs derived from 
DM1 hESCs. Changes in INSR exon 11 were studied using 
reverse transcription–PCR (RT–PCR), as the two isoforms 
of this gene were readily expressed in MPCs. Metformin cor-
rected INSR exon 11 splicing defects in DM1 MPCs, increas-
ing the inclusion from 18% (±2.3) to 34% (±1.8) at a dose of 
25 mmol/l (Figure 3a). A similar shift towards an increased 
proportion of INSR exon 11 inclusion was also observed in 
wild-type MPCs, demonstrating the ability of metformin to 
regulate alternative splicing independently of the presence of 
the DM1 mutation. This analysis was extended to two other 
well-described alternative RNA splicing events associated with 
DM1, TNNT2 exon 5 and Clcn1 exon 7a.17,25 This was based 
on the use of minigenes because the two isoforms of these 
genes are only expressed in heart and skeletal muscle.25,26 The 
transient transfection of the minigenes in DM1 MPCs treated 
with 25 mmol/l metformin showed a statistical lowering of the 
percentage of inclusion of TNNT2 exon 5 inclusion (from 51 ± 
0.5% to 17 ± 0.4%) and Clcn1 exon 7a inclusion (from 36% to 
23 ± 2.03%) to levels similar to those quantified in wild-type 
MPCs (22 ± 1.5% and 20 ± 1.5%, respectively) (Figure 3b).
Overall effects of metformin treatment on alternative 
RNA splicing
To better understand the overall effects of metformin on 
gene expression and alternative RNA splicing, DM1 MPCs 
treated with 25 mmol/l metformin were analyzed using deep 
RNA sequencing. Treatment with 10 mmol/l of metformin 
was also included in this analysis as this dose induced a 
slight effect on INSR splicing (Figure 3a). A total of 63 and 
1,171 genes in DM1 MPCs were regulated with an absolute 
log2-fold change of ≥1 (P ≤ 0.05) in response to 10 and 25 
mmol/l metformin, respectively. In these sets of genes, bio-
logical processes corresponding to cell cycle, response to 
DNA damage, cytoskeleton and ATP binding were enriched 
(Table 1 and Supplementary Tables S1 and S2). Downregu-
lation of RBM3 transcript was also detected in DM1 MPCs 
treated with 25 mmol/l metformin with fold changes of 0.33 
(adjusted P value: 1.28 × 10−7) confirming our previous obser-
vations (Figure 1). Analysis at the exonic level identified vari-
ations in 95 and 416 exons regulated above 10% (P ≤ 0.05) 
at drug concentrations of 10 and 25 mmol/l, respectively 
(Figure 4a; Supplementary Figure S2a and Supplemen-
tary Table S3). Eighty-nine common splicing events were 
found to be deregulated at both concentrations. Of the 20 
splicing events most highly regulated (>20%) by 25 mmol/l 
metformin, 19 were confirmed by RT–PCR in DM1 MPCs 
Figure 3 Characterization of metformin treatment on DM1-associated splicing defects in DM1-mutated mesodermal precursor cells 
(MPCs). (a) Alternative splicing of INSR exon 11 was analyzed with reverse transcription–PCR (RT–PCR) in wild type and DM1 MPCs treated 
with a range of metformin doses for 48 hours. (b) Alternative splicing of TNNT2 exon 5 and Clcn1 exon 7a were analyzed with RT–PCR in 
wild type and DM1 MPCs. Transfected DM1 MPCs were also treated for 48 hours with vehicle or 25 mmol/l metformin. Data (mean + SD) were 
analyzed with analysis of variance and the Kruskal–Wallis post hoc test. *P < 0.05, ***P < 0.001. DM1, myotonic dystrophy type I; WT, wild type.
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Table 1 Biological process enriched in genes and splicings regulated by 
metformin
Biological process
Nb of 
genes P valuea
Fold  
enrichment
1,171 genes regulated by 25 mmol/l metformin (absolute log2-fold change 
> 1)
  Cell cycle 140 5.0 E-40 33.09
  ATP binding 115 3.3 E-05 6.38
  Cytoskeleton 112 1.1 E-05 8.51
  Response to DNA damage stimulus 55 1.6 E-10 10.37
416 splicing events regulated by 25 mmol/l metformin (>10%)
  Cytoskeleton 53 3.3 E-04 4.26
  Nuclear lumen 48 3.1 E-02 2.32
  Kinase 30 1.6 E-02 1.76
  RNA binding 24 3.2 E-02 1.87
aOne tail Fischer exact probability value used for gene-enrichment analysis, 
using DAVID software and the human genome as reference.
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(Figure 4b). Gene set enrichment analysis of the 416 splic-
ing events regulated at 25 mmol/l identified sets of genes 
involved with the cytoskeleton, nuclear lumen, RNA binding, 
or with kinase activity (Table 1). Interestingly, most of the 
deregulated genes are also enriched in genes involved with 
the cytoskeleton (Table 1). None of the deregulated genes 
are associated with an alternative splicing modulation.
As our initial results indicated that metformin led to a reduced 
expression of RBM3, possible involvement of this splice factor in 
the regulation of alternative splicing by metformin was explored 
Figure 4 Genome-wide analysis of alternative splicing regulation by metformin. (a) Number of splice events modified by metformin 
treatment at 10 or 25 mmol/l. The number of common splice events modified at both concentrations is also indicated. (b) Reverse transcription–
PCR (RT–PCR) validation of alternative splicing events identified by RNA sequencing in myotonic dystrophy type I (DM1) mesodermal precursor 
cells (MPCs) treated for 48 hours using 10 and 25 mmol/l of metformin. (c) Ten of the splicing events most regulated by metformin were analyzed 
by RT–PCR in DM1 MPCs transfected for 48 hours with a siRNA specific for RBM3 or exposed for 48 hours to treatment with 25 mmol/l 
metformin. Data (mean + SD) were analyzed with analysis of variance and the Kruskal–Wallis post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001.
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using a siRNA transfection approach on 10 of the newly identi-
fied splicing events most altered by drug treatment. Thus, we 
compared the effects of metformin and transient extinction of 
RBM3 in DM1 MPCs. Downregulation of RBM3 expression 
induced similar results to metformin treatment for 7 out of 10 
splicing events. These results strongly suggested that RBM3 
contributes to the mechanism of action of metformin on alterna-
tive splicing (Figure 4c and Supplementary Figure S2b,c).
As RBM3 is described to be alternatively spliced, we also 
tested the possibility that the decreased expression of RBM3 
induced by metformin was not associated to an effect of metfor-
min on the expression of one of the alternate splice isoforms of 
RBM3. First, we analyzed, by RT–PCR, the expression profile 
of the 11 transcripts for RBM3 that are described in ENSEMBL 
data bank in the presence and absence of metformin treat-
ment. Among those, we detected six RBM3 variant transcripts 
independently of metformin treatment (Figure 5a). We have 
next quantified the expression of each variant by quantitative 
PCR. Our results indicate that metformin treatment does not 
modify alternate splicing of RBM3 transcripts (Figure 5a,b). 
In parallel, as two additional transcripts for RBM3 have been 
described as candidates for nonsense-mediated mRNA 
decay process in NCBI data base, we also analyzed their 
expression after treatment with nonsense-mediated mRNA 
decay inhibitors, such as cycloheximide.27 We first validated 
the effect of different concentrations of cycloheximide on the 
decay of unstable mRNA such as c-FOS. Our results indicate 
that, independently of the dose of cycloheximide used, the 
two RBM3 transcripts are not expressed in our cell cultures 
in presence or not of metformin (Supplementary Figure S3). 
Altogether, our results indicate that the decreased RBM3 
expression observed after metformin treatment is not corre-
lated to a change in alternative splicing of RBM3 transcript.
Molecular mechanisms involved in the regulation of 
alternative RNA splicing by metformin
We next seek to understand the signaling pathways by which 
metformin treatment leads to a modification of splicing fac-
tor expression and consequently a modification of alternative 
splicing. The well-known antidiabetic action of metformin has 
been correlated to the inhibition of complex I of the respira-
tory chain,28 raising the intracellular AMP/ATP ratio, a signal 
that finally triggers the downstream activation of AMPK.28,29 
Activity of respiratory chain complex I and AMP intracellular 
levels were monitored in DM1 MPCs after metformin treat-
ment. Spectrometric measurements confirmed that progres-
sive doses of metformin specifically inhibited the respiratory 
chain complex I in a dose-dependent manner up to a con-
centration of 10 mmol/l (Figure 6a). At 25 mmol/l, metformin 
also inhibited complexes II and IV and, to a lesser extent, 
complex V. This led to an increased AMP/ATP ratio, as deter-
mined by high-performance liquid chromatography (Figure 
6b). The potential role of AMPK activation in alternative RNA 
splicing induced by metformin was tested by challenging DM1 
MPCs with the AMPK activator AICAR (5-aminoimidazole-
4-carboxamide 1-β-D-ribofuranoside, Acadesine, N1-(β-D-
ribofuranosyl)-5-aminoimidazole-4-carboxamide). Treatment 
of DM1 MPCs with 2 mmol/l AICAR for 24 hours promoted the 
downregulation of RBM3 (Figure 6c) together with changes 
in exon inclusions on five of the splicing events most regulated 
by metformin (MDM4 exon 7, GPCPD1 exon 5, CCNL2 exon 
7, RAGE exon 3, and ZFAND1 exon 3) (Figure 6d and Sup-
plementary Table S3). Strikingly, neither AICAR treatment 
nor downregulation of RBM3 expression seemed to modu-
late the INSR exon 11 splicing in DM1 MPCs, suggesting that 
metformin might activate additional molecular pathways to 
mediate its global effect on alternative splicing (Figure 6e).
Impact of metformin on DM1-associated splicing defects 
in myoblasts
The potential interest of metformin in the pathological context 
of DM1 was evaluated by measuring the effect of metformin 
treatment on 20 splicing events that showed graded changes 
correlated with muscle strength in a cohort of 50 DM1 sub-
jects.30 This was accomplished by using primary cultures of 
myoblasts derived from two healthy individual and two distinct 
DM1 patients. In addition, splicing of INSR exon 11 and TNNT2 
exon 5, previously studied by the use of minigenes in DM1 
MPCs (Figure 3), was analyzed as they are also expressed in 
cultured myoblasts. Metformin promoted changes in alterna-
tive splicing of exons ≥10% for six of these genes (Figure 7 
and Supplementary Figure S4). The effect of metformin was 
beneficial on INSR exon 11, TNNT2 exon 5, ATP2A1 exon 22, 
DMD exon 71, DMD exon 78, and KIF13A exon 32, as the iso-
form ratio shifted towards control values. The drug did not affect 
the 16 other splicing events that were tested (including those 
for which no splicing event is observed in absence of treatment 
in this cell type) (Supplementary Figure S5). The involvement 
of AMPK activation in the regulation of the six DM1 splicing 
defects modified by metformin was tested in one of the DM1 
myoblast cultures. Experiments confirm a partial implication of 
the AMPK as AICAR treatment restored the splicing defects 
of ATP2A1 exon 22 and TNNT2 exon 5, while no modulations 
of DMD exon 78 and INSR exon 11 were observed (Figure 7 
and Supplementary Figure S4). Interestingly, AICAR pro-
moted the inclusion of DMD exon 71. The splicing defect of 
KIF13A exon 32, not detected in these myoblasts, could not be 
analyzed. The efficacy of metformin treatment on DM1-asso-
ciated splicing defects was next compared to pentamidine, a 
compound shown to revert some splicing defects associated 
with DM1.6 Interestingly, a decreased expression of RBM3 is 
also observed after pentamidine treatment (Supplementary 
Figure S6a,b). Concordant with this observation, similar effi-
ciency was observed between metformin and pentamidine 
with reference to their ability to restore the inclusion of ATP2A1 
exon 22, corresponding to the most affected splicing event in 
muscle biopsies of DM1 patients,30 as well as on DMD exon 
71 (Figure 7, Supplementary Table S4, and Supplementary 
Figures S4 and  S6c). However, in contrast to metformin treat-
ment, no significant effect (>10%) of pentamidine was detected 
on DMD exon 78, INSR exon 11, and TNNT2 exon 5.
In vivo effects of metformin on RNA alternative splicing
In order to explore the effects of metformin on alternative splic-
ing at therapeutic concentrations in humans, we investigated 
patients currently being treated with metformin for Type 2 dia-
betes. To perform a clinical trial in which metformin would be 
temporarily replaced by another antidiabetic drug, namely sita-
gliptin, the lack of efficacy of sitagliptin was verified on INSR 
exon 11 alternative splicing in preliminary experiments carried 
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out in vitro on peripheral blood lymphocytes (PBLs) (Supple-
mentary Figure S7a,b). Fifteen diabetic patients, who had 
been treated with a stable dose of metformin between 2.1 and 
3 g/day for more than a year, were recruited in a study where 
metformin was replaced for 1 month by sitagliptin, and RNA 
alternative splicing was explored in PBLs (NCT 01349387). 
There was no change in blood glucose levels during the course 
of the study. Of the splicing events identified in response to 
metformin, we chose alternative splicing of INSR exon 11, 
which is expressed in most tissues. Because of its low level of 
Figure 5 Analysis of the effect of metformin on RBM3 alternative splicing. (a) Expression profile of 11 RBM3 transcripts and 2 
nonsense-mediated mRNA decay candidates in myotonic dystrophy type I (DM1) mesodermal precursor cells (MPCs) treated or not with 
25 mmol/l of metformin for 48 hours. Primer assay corresponds to a specific pair of primers designed to match with distinct splice variants 
of RBM3. (b) Expression level of RBM3 variants were quantified in DM1 MPC after a 48 hours treatment with 25 mmol/l metformin by 
reverse transcription–quantitative PCR. Primer assays that amplified one variant were used as followed: for RBM3-03, primer assay 6; for 
RBM3-04, primer assay 2; for RBM3-05, primer assay 7; for RBM3-06, primer assay 3; for RBM3-07, primer assay 4; for primer RBM3-10, 
primer assay 5. Data are represented as mean + SD. Expression level of each variant was normalized on 18S and on the expression in 
universal RNA. NMD, nonsense-mediated mRNA decay.
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expression in these cells, INSR +/− exon 11 transcripts were 
analyzed with quantitative PCR. Analysis confirmed that met-
formin triggered INSR exon 11 inclusion in this clinical setting 
(Figure 8a). Alternative splicing of FAS (CD95) exon 6 was 
analyzed in order to identify an additional splicing event that 
could be measured in PBLs from treated patients. FAS exon 6 
exclusion was also affected by therapeutic doses of metformin 
in diabetic patients, giving rise to a shift from the anti- to the 
proapoptotic isoform of the protein (Figure 8b,c).
Discussion
The main result of this study is the demonstration that met-
formin, the antidiabetic biguanide, affects the alternative 
RNA splicing machinery. Our results point to a molecular 
mechanism that involves, at least partially, the activation of 
AMPK and modulation of the RBM3 RNA-binding protein. 
The demonstration that metformin modulates several splic-
ing events in vitro and in vivo, including some altered in DM1, 
suggests that it would be worthwhile to evaluate the efficacy 
of metformin treatment in alleviating other symptoms than 
those related to insulin resistance.
The importance of gene regulation at the level of RNA tran-
scripts by alternative splicing has been reported increasingly 
in fields such as development,31 cancer,32 metabolism,33 and 
monogenic diseases.1 Alternative RNA splicing thus opens 
new opportunities for therapeutic approaches.34 However, 
it seems unlikely that selective modulation of a single spe-
cific splicing event could be carried out without generating 
concomitant adverse effects. However, this goal might be 
achieved with the use of marketed drugs whose biodistribution 
Figure 6 Intracellular modifications induced by metformin and involvement of AMPK in splicing control. (a) Activities of the different 
complexes of the respiratory chain were evaluated by spectrometry in myotonic dystrophy type I (DM1) mesodermal precursor cells (MPCs) 
treated for 48 hours with 5, 10, and 25 mmol/l metformin. Representative graph of the results obtained with three different samples. CI to 
CV represent the different complexes of the respiratory chain. (b) The effect of metformin on intracellular AMP/ATP content was quantified 
with high-performance liquid chromatography. Data (mean + SD) were analyzed with analysis of variance (ANOVA) and the Kruskal–Wallis 
post hoc test. (c) AICAR inhibits the expression of RBM3, analyzed by western blot. Data (mean + SD) were analyzed with ANOVA and the 
Kruskal–Wallis post hoc. (d) AICAR promotes changes in MDM4 exon 7, GPCPD1 exon 5, CCNL2 exon 7, RAGE exon 3, and ZFAND1 exon 
3. (e) The alternative splicing of INSR exon 11, analyzed in DM1 MPCs by reverse transcription–PCR, is not modified by a 24-hour AICAR 
treatment or the downregulation of RBM3 induced by the transfection of siRNA for 48 hours. Data (mean + SD) were analyzed with ANOVA 
and a Tukey–Kramer post hoc test. *P < 0.05, ***P < 0.001. AICAR, 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside, Acadesine, 
N1-(β-D-ribofuranosyl)-5-aminoimidazole-4-carboxamide).
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is known and which regulate alternative splicing.4,5,35 These 
compounds could be reconsidered as modulators of alterna-
tive RNA splicing in addition to the effects on cellular targets 
for which they have been screened. It is worth mentioning 
that an analysis by exon array demonstrated that compounds 
such as clotrimazole, flunarizine, and chlorhexidine targeted 
different signal transduction pathways and caused distinct 
changes in alternative splicing of a number of genes.4 This 
suggests that discrete targeting of the alternative splicing of 
specific genes associated with a particular disease may be 
possible with selected pharmacological agents.
In this context, we focused on metformin, which is indicated 
as a first-line oral therapy for treatment of hyperglycemia in 
individuals with Type 2 diabetes. Even though this drug has 
been in use for several decades, most of its cellular effects 
are still under investigation and new emerging effects, such as 
inhibition of cell proliferation, suggest its potential repurposing 
to treat cancer. Metformin was recently reported to selectively 
inhibit the translation of several RNA-binding proteins concom-
itantly with its blockade of cell proliferation.7 Our results confirm 
that metformin treatment downregulates RBM3 in DM1 MPCs 
and induces splicing of a restricted set of primary transcripts. 
The cellular model we used allowed us to verify the involve-
ment in this process of AMPK, the classical cellular target of 
metformin.28,29 The characterization of metformin treatment in 
DM1 MPCs pointed to a signal associated with energy deple-
tion and blockade of cell proliferation induced by inhibition of 
complex 1 of the mitochondria, ATP decrease, and activation 
Figure 7 Metformin impacts several splicing defects associated with DM1 in mutated human myoblasts. Reverse transcription–PCR 
analysis of DM1-associated splicing defects in myoblasts from two DM1 patients and two healthy individuals treated for 48 hours with 25 
mmol/l metformin or for 24 hours with 75 µmol/l pentamidine or AICAR 2 mmol/l. Representative data from two independent experiments are 
shown. AICAR, 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside, Acadesine, N1-(β-D-ribofuranosyl)-5-aminoimidazole-4-carboxamide; 
DM1, myotonic dystrophy type I; WT, wild type.
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of the AMPK metabolic sensor. This reveals a molecular signa-
ture at the level of RNA transcripts that is associated with met-
abolic stress and similar to that identified for other genotoxic 
or oxidative stress inducers.36,37 In parallel to these events, the 
absence of modulation of several DM1-associated splicing 
defects by the AMPK activator, AICAR, reveals the existence 
of additional molecular mechanisms by which metformin mod-
ulates the alternative splicing of certain primary transcripts. 
Metformin has been described as diminishing tyrosine kinase 
receptor signaling in vitro and in vivo.38,39 These tyrosine kinase 
receptors include epidermal growth factor receptor, the signal-
ing pathway of which controls INSR exon 11 inclusion through 
inhibition of hnRNPA1 and hnRNPA2B1 expression.40 Whether 
such a mechanism is involved in other alternative splicing 
events regulated by metformin remains to be explored.
Among the regulated splicing events, we explored the 
impact of metformin treatment on those affected in DM1, 
because this drug is used to treat Type 2 diabetes in patients 
with DM1.8 This well-tolerated drug could be an efficient way 
to alleviate DM1 missplicing in several organs affected by this 
multisystemic disease. It is commonly thought that most clini-
cal manifestations of DM1 are linked with defects in alterna-
tive splicing due to the loss of MBNL1 function.41 Accordingly, 
most attempts at finding treatments for this as yet incurable 
disease have focused on the release of MBNL1 from ribonu-
cleoprotein intranuclear inclusions, and reversion of splicing 
defects has been observed with ribozymes,42 antisense oli-
gonucleotides,43 and chemical compounds such as pentami-
dine.6,44 Metformin is shown here to alter splicing through a 
different mechanism that targets the splicing machinery. 
The downregulation of RBM3 by metformin in DM1 but also 
wild-type MPCs reveals a mode of splicing regulation that 
is not specific to DM1. The impact of metformin on DM1-
associated splicing defects could be in part defined by the 
overlap between the targets of RBM3 and those of MBNL1. 
Our results indicated that metformin is capable of alleviating 
several splicing defects in cells differentiated from pluripotent 
stem cells derived from a DM1-mutant embryo, as well as 
in myoblasts sampled from DM1 patients. To focus on DM1 
splicing defects that would be therapeutically significant, we 
analyzed the impact of metformin treatment in DM1 myoblasts 
on 20 splicing defects identified in DM1 skeletal muscle tissue 
that were correlated with muscle weakness using a genome-
wide approach.30 Experiments confirmed the partial modula-
tion of these splicings by metformin, including ATP2A1 exon 
22, identified as the most affected in correlation with muscle 
weakness in DM1 patients, and INSR exon 11 or TTN exon 
5 that belong to the early transition splicing group that are 
strongly affected by DM1 (>30% shift of exon inclusion), yet 
not associated with muscle weakness (r ≤ 0.5).30 Within the 
DMD transcript, metformin enhanced the inclusion of exon 78 
but also increased the DM1-associated skipping of exon 71. 
Figure 8 Regulation of alternative splicing of INSR exon 11 and FAS exon 6 by therapeutic doses of metformin can be followed in vivo 
in patients. (a) The INSR + exon 11 / − exon 11 ratio was monitored with reverse transcription–quantitative PCR (RT–qPCR) in peripheral 
blood lymphocytes from diabetic patients treated with metformin (V0), with sitagliptin instead of metformin for 1 month (V1) and 1 month after 
restarting metformin treatment (V2). (b,c) The same samples were also analyzed with RT–PCR to quantify the alternative splicing of FAS exon 
6, which is also regulated by metformin. Data represent the individual responses in each group (n = 15 patients) and were analyzed with the 
Wilcoxon paired test. *P < 0.05, ***P < 0.001. NS, nonsignificant.
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A transcript lacking the DMD exon 71 is normally expressed 
in normal skeletal muscle but is overexpressed in DM1 
patients. Immunoblot analysis shows no change in dystrophin 
protein expression in skeletal muscle between DM1 and non-
DM individuals,45 indicating that the functional impact of DMD 
exon 71 exclusion remains to be functionally tested. Nota-
bly, the skipping of DMD exon 71 is also observed in DM1 
myoblasts in response to pentamidine treatment, indicating 
that treatments that restore MBNL1 expression also provide 
partial correction of the DM1-associated splicing defects. In 
parallel to the modulation of splicing, metformin could be of 
interest for DM1 as an activator of AMPK. AICAR treatment 
tested on muscle function in mdx mice46 has been reported 
to promote significant improvements in disease phenotype (a 
gain in body and muscle weight, a decrease in muscle inflam-
mation and in the number of fibers with central nuclei and an 
increase in fibers with peripheral nuclei), including an increase 
in overall behavioral activity and significant gains in forelimb 
and hind limb strength. Since metformin is commonly used 
to treat insulin resistance in DM1 patients at doses that were 
shown in the present study to induce shifts in transcript iso-
form ratios, we decided to investigate modulation of splicings 
by metformin as well as drug efficacy on several functional 
parameters in a clinical trial with DM1 patients (EudraCT 
number: 2013-001732-21). This study will determine the 
therapeutic potential of metformin to treat DM1 patients for 
aspects of their disorder other than insulin resistance.
Considering that metformin has been used for decades in 
millions of patients without major toxicity, one may consider 
targeting alternative splicing in order to obtain a therapeu-
tic effect. Accordingly, a systematic search for the effects on 
alternative splicing of drugs that are already in current use 
may eventually allow clinicians to extend their indications 
to diseases in which a change in isoform ratios of specific 
genes may be therapeutically beneficial. For example, the 
two isoforms of FAS (CD95) have opposite effects, being 
either pro- or antiapoptotic,47,48 and, in PBLs sampled from 
diabetic patients, treatment with metformin induced a shift 
from the antiapoptotic variant to the proapoptotic variant of 
CD95. This effect could influence FAS-mediated apoptosis, 
which could be relevant for Ewing and other sarcomas49 or 
autoimmune lymphoproliferative syndromes resulting from 
the failure of FAS exon 6 inclusion.50
Materials and Methods
Reagents. Primers, probes, and siRNA sequences are listed 
in Supplementary Table S5. The RBM3 siRNA came from 
Qiagen (Courtaboeuf, France). Sitagliptin was obtained 
from Januvia 100-mg tablets (MSD Merck Sharp & Dohme 
Ltd, Hoddesdon, UK). Metformin, AICAR (5-Aminoimid-
azole-4-carboxamide 1-β-D-ribofuranoside, Acadesine, 
N1-(β-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide), 
pentamidine isethionate salt, cycloheximide, staurosporine, 
and ionomycin were obtained from Sigma. Primary antibodies 
used in this study were raised against SRSF1 (Clinisciences, 
Nanterre, France; LSB2340, 1/500), RBM3 (Abcam, Cam-
bridge, UK; ab134946, 1/1,000), SFPQ (Abcam; ab117617, 
1/500), RBM45 (Abcam; ab105770, 1/200), SRSF6 
(Clinisciences; LS-B5712, 1/2,000), CELF1 (Millipore, Darm-
stadt, Germany; 05621, 1/2,000), Ki-67 (Millipore; MAB4190), 
and ACTB-peroxidase (Sigma-Aldrich, Saint-Louis, MO; 
A3854). Horseradish peroxidase-conjugated secondary 
antibodies used for western blot were goat anti-mouse IgG-
horseradish peroxidase or goat anti-rabbit IgG-horseradish 
peroxidase (1:10,000; Amersham Bioscience, GE Health-
care, Saclay, France). MBNL1 was detected by the use of the 
MANDYS1 antibody, kindly provided by Prof. Glenn Morris 
(Center for Inherited Neuromuscular Disease, Oswestry, UK) 
and obtained from the MDA Monoclonal Antibody Resource.
Pluripotent stem cells culture. The two hESC lines used in this 
study came from the Department of Embryology and Genet-
ics of the Vrije Universiteit, AZ-VUB Laboratory, Brussels, 
Belgium: the VUB03_DM1 (XX, passages 66–67) carrying 
the DM1 mutation (1,330 CTG repeats) and the VUB01_CTL 
(XY, passage 83) used as a control.51 Human pluripotent 
stem cells were maintained on a layer of mitotically inacti-
vated murine embryonic STO fibroblasts in Knockout Dul-
becco’s Modified Eagle’s Medium supplemented with 20% 
knockout serum replacement, 1 mmol/l Glutamax, 1 mmol/l 
nonessential amino acids, 1% penicillin/streptomycin, 0.1% 
β-mercaptoethanol, and 5 ng/ml recombinant human FGF2 
(all from Invitrogen, Carlsbad, CA). Medium was changed 
daily and cells were passaged every 5–7 days. Manual dis-
section was routinely used to passage the cells.
Differentiation of hESC lines in MPCs. MPCs were gener-
ated by differentiation from hESCs according to the proto-
col described previously by Marteyn et al.19 MPCs derived 
from the VUB03_DM1 and VUB01_CTL hES cell lines were 
cultured on 0.1% gelatin-coated flasks and plates (Sigma-
Aldrich) using Knockout Dulbecco’s Modified Eagle’s Medium 
(Invitrogen) supplemented with 20% fetal bovine serum 
(Eurobio, Les Ulis, France), 1 mmol/l Glutamax (Invitrogen), 
1 mol/l nonessential amino acids (Invitrogen), and 0.1% 
β-mercaptoethanol (Invitrogen).
Culture of human myoblasts. Control and DM1 myoblasts were 
obtained from the Myobank in accordance with the French 
legislation on ethical rules (kindly provided by Dr. D. Furling). 
Two control myoblasts were originally isolated from the quad-
riceps of a 5-day-old infant (CHQ) and from a week 14 fetus 
(Me16). Two DM1 myoblasts were originally isolated from the 
quadriceps of a 11-day-old infant carrying more than 2,500 
CTG (DM11) and from a week 14 fetus carrying 800 CTG 
(DM16). WT#1 and WT#2 correspond to Me16 and CHQ 
myoblasts while DM1#1 and DM1#2 match with DM11 and 
DM16 myoblasts. Cells were cultured on 0.1% gelatin-coated 
flasks and plates using Dulbecco’s Modified Eagle’s Medium-
F12 + glutamax medium (Invitrogen) supplemented with 20% 
fetal bovine serum (Eurobio).
Culture of human PBLs. Freshly isolated wild-type and mutated 
PBLs, provided by Dr. Guillaume Bassez (CHU Henri Mon-
dor, Creteil, France), were obtained from the Genethon DNA 
and Cells Bank (Evry, France). Cells were thawed and cul-
tured in RPMI medium supplemented with 20% of fetal bovine 
serum (Eurobio) and 1% penicillin–streptomycin (Invitrogen) 
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according to cell bank instructions. Chemical treatments were 
performed once a day for 2 days. Freshly isolated PBLs from 
diabetic patients treated by metformin or sitagliptin were 
obtained from the CERITD (Evry, France) (NCT 01349387).
Measurement of sitagliptin activity and cell viability. Sita-
gliptin activity was measured in vitro using the luminescent 
DPPIV-Glo Protease Assay (Promega, Madison, WI) accord-
ing the manufacturer’s instructions. Viability of lymphocytes 
treated with a range of sitagliptin doses was monitored with 
the CellTiter-Glo assay (Promega) according the manufac-
turer’s instructions.
Transfection of DNA constructs and siRNAs. MPCs were 
seeded in 24-well plates and transfected with 600 ng of plas-
mid, 0.6 µl of PLUS (Invitrogen) and 1.5 µl Lipofectamine 
LTX (Invitrogen). The RTB300 minigene used to analyze 
the splicing of exogenous human cTNT transcripts was 
kindly provided by Prof. TA Cooper (Baylor College of Medi-
cine, Houston, TX). We constructed the minigene used to 
study Clcn1 exon 7a splicing as described by Kino et al.26 
The genomic fragment covering exons 6 to 7 from mouse 
genomic DNA was PCR amplified using the Clcn1 cloning 
primers described in Supplementary Table S5, cloned in 
the pCR-BluntII-TOPO vector (Invitrogen) using the BamHI/
SalI restriction enzymes and then subcloned into the BglII-
SalI site of pEGFP-C1 (Clontech, Mountain View, CA). For 
siRNA transfection, MPCs were seeded in 24-well plates 
and transfected with 10 nmol/l siRNA RBM3 (Qiagen) listed 
in Supplementary Table S5 using 2.5 µl LipoRNAiMax 
(Invitrogen).
RNA sequencing library preparation and sequencing. Sequenc-
ing libraries were prepared according to the Illumina TruSeq 
Stranded mRNA Sample Prep Kit (according to manufactur-
er’s protocol) (Illumina, San Diego, CA). A 2 × 101 bp paired-
end sequencing was performed on the HiSeq2000 instrument, 
using half a lane per sample, to produce on average 80 million 
read pairs per sample (160 million sequences) with an average 
insert length of 130 bp. Trimmomatic,52 Tophat2,53 Picard suite 
(http://www.broadinstittute.github.io/picard), RNA-SeQC,54 and 
in-house metrics were used to evaluate data quality.
RNA sequencing data analysis and identification of differential 
genes and splicing events. Reads were aligned using TopHat2 
(v2.0.853). TopHat2 was run with the assistance of gene anno-
tations (Illumina’s iGenomes based on EnsEMBL r70), which 
means that the alignment was performed in three steps: tran-
scriptome mapping, genome mapping, and spliced mapping. 
The minimum and maximum intron lengths were also re-
evaluated, respectively, to 30 and 1,200,000 to maximize the 
number of introns detected. The mate inner distances were 
set to their corresponding values. Alignment files in bam for-
mat were then filtered to removed poor mapping quality score 
(<10) and not primary alignments and read pairs with one 
single read mapped were filtered using samtools (v0.1.855).
For the differential gene expression analysis, reads map-
ping to genes were first quantified using the HTSeq-count 
script provided by the HTSeq python package (v0.5.456). The 
R/Bioconductor package DESeq2 (v1.4.557) was then used to 
identify genes regulated by the drug treatment. A filter was then 
applied to DESeq2 results to select genes with an adjusted 
P value ≤0.05 and the mean of normalized counts ≥10.
For the alternative splicing analysis, reads crossing the 
exon–exon junction (“junction reads”) were extracted from 
the read alignment files to detect the exon skipping events. 
In order to avoid spurious read alignments, we applied addi-
tional filters for the junction reads considered: no indels at the 
junction site, no hard clipping, and a minimal overlap of 4 bp 
over the junction site. FasterDB58 gene and exon annotations 
were used as a guide to detect known and new exon skip-
ping events. For each exon skipping event detected across 
all samples, junction reads corresponding to the inclusion of 
the exon and junction reads corresponding to the exclusion 
of the exon were quantified. The differential analysis was per-
formed using KissDE, an R package developed as part of the 
KisSplice post-processing workflow.59 KissDE works on pairs 
of variants for which read counts are available in each repli-
cate of each condition and tests if a variant is enriched in one 
condition. Counts are modeled using a negative binomial dis-
tribution. KissDE fits a generalized linear model and tests for 
the effect of an interaction between the variant and the condi-
tion using a likelihood ratio test with a 5% false discovery rate 
to control for multiple testing. A percent splicing index (PSI or 
Ψ) value was then estimated for each sample as the ratio of 
inclusion junction reads to the sum of inclusion and exclusion 
junction reads. As the datasets are paired, the difference of 
Ψ values for each event (deltaPSI or ΔΨ) was calculated as 
the median of ΔΨ values for each replicate. A filter was then 
applied on exon skipping events detected to select significant 
variants with an adjusted P value ≤0.05 and ΔΨ value ≥10%.
Gene expression and splicing analysis by RT–PCR. Total 
RNA was extracted using the RNeasy Micro/Mini kit (Qiagen) 
and reverse transcribed using random hexamers and Super-
script III Reverse Transcriptase kit (Invitrogen). For splicing 
analysis, PCR amplification was carried out with recombinant 
Taq DNA polymerase (Invitrogen) and the primers listed in 
Supplementary Table S5. The amplification was performed 
using a first step at 94 °C for 3 minutes followed by 30 cycles 
of 45 seconds at 94 °C, 30 seconds at 55 °C, 30 seconds at 
72 °C, and finished with a final 10 minutes extension at 72 
°C. The PCR products were quantified using the Bioanalyzer 
2100 and DNA 1000 LabChip kit (Agilent, Santa Clara, CA). 
Primers used for splicing analysis in human myoblasts are 
described in Nakamori et al.30 except those used to analyze 
ATP2A1 exon 22 and TNNT2 exon 5 splicings.
RBM3 gene expression and splicing analyses by quantita-
tive PCR. Quantitative PCR reactions were carried out in 
384-well plates using a QuantStudio 12K Flex Real-Time 
PCR System (Applied Biosystems, ThermoFisher Scientific, 
Illkirch Graffenstaden, France) with Power SYBR Green 2× 
Master Mix (Life Technologies, ThermoFisher Scientific, 
Illkirch Graffenstaden, France), 0.5 µl of cDNA, and 100 
nmol/l of primers (Invitrogen) in a final volume of 10 µl. 
Detailed information on the primers sequences is provided 
in Supplementary Table S5. The relative expression level 
of each gene was calculated with the method described by 
Pfaffl.60 A precise description of samples preparation and 
Molecular Therapy—Nucleic Acids
Metformin Modifies Alternative Splicing in DM1
Laustriat et al.
12
experiment procedure are compiled in Supplementary 
Table S6. Data were expressed as mean ± SD.
Protein extraction and western blot analysis. Cells were 
homogenized in radioimmunoprecipitation assay buffer 
(Sigma-Aldrich) containing 1% protease inhibitors (Sigma-
Aldrich) and 10% phosphatase inhibitors (Roche, Paris, 
France). After electrophoresis on 4–12% Nu-PAGE Bis-Tris 
gels (Invitrogen) under reducing conditions, proteins were 
transferred to nitrocellulose membranes (Invitrogen), blocked 
with phosphate-buffered saline (PBS) containing 0.1% 
Tween-20 and 5% bovine serum albumin (BSA) or 5% non-
fat dry milk, depending on the primary antibody used, and 
incubated overnight with the primary antibody diluted in PBS 
containing 0.1% Tween-20 and 5% BSA or 5% nonfat dry 
milk. Membranes were then incubated for 1 hour with the cor-
responding secondary antibody and immunoreactive protein 
bands were detected by ECL Plus detection reagents (Amer-
sham Bioscience) according to the manufacturer’s protocol 
using an ImageQuant CDD camera (GE Healthcare).
Enzymatic activities. Respiratory chain enzyme activities 
were spectrophotometrically measured using a Cary 50 
UV–visible spectrophotometer (Varian, Les Ulis, France) as 
described by Bénit et al.61 Mitochondrial substrate oxidation 
was polarographically estimated using a Clark oxygen elec-
trode (Hansatech Instruments, Norfolk, England) in a mag-
netically stirred 250-µl chamber maintained at 37 °C in 250 
µl of a respiratory medium consisting of 0.3 mol/l mannitol, 
5 mmol/l KCl, 5 mmol/l MgCl2, 10 mmol/l phosphate buffer (pH 7.2), and 1 mg/ml BSA, plus substrates or inhibitors as 
described by Rustin et al.62 Protein concentration was mea-
sured according to the Bradford assay.
Viability, cytotoxicity, and caspase assay. MPCs DM1 were 
seeded at 5,000 cells/well in 96-well plate and were treated 
with dose range of metformin for 48 hours or dose range of 
ionomycin and staurosporine for 24 hours. Viability, cytotoxic-
ity, and apoptosis events were assessed using the ApoTox-
Glo Triplex Assay (Promega). After incubation of cells with 
the “Viability/Cytotoxicity reagent” for 50 minutes at 37 °C, 
the resulting cell viability and cytotoxicity fluorescences were 
measured respectively at 400Ex/505Em and 485Ex/520Em 
using the CLARIOstar microplate reader (BMG LABTECH, 
Champigny-sur-Marne, France). Cells were then incubated 
with the “Caspase-Glo 3/7 reagent” for 30 minutes at room 
temperature in dark, and caspase activation (a hallmark of 
apoptosis) was determined with luminescence measurement 
using the CLARIOstar microplate reader (BMG LABTECH).
Ki-67 proliferation assay. DM1 MPCs were treated with met-
formin dose range for 48 hours, daily repeated. After treat-
ment, cells were fixed with 4% paraformaldehyde in PBS for 
15 minutes at room temperature and incubated overnight at 4 
°C with Ki-67 antibody diluted in PBS solution with 0.1% BSA 
and 0.3% Triton. After three washings in PBS, cells were incu-
bated for 1 hour at room temperature with Alexa Fluor 647 
goat anti-mouse IgG (ref. A21235; 1:1,000; Invitrogen) and 
Hoechst (ref. H3570; 1:3,000; Invitrogen) diluted in the same 
blocking solution as previously. After three washings in PBS, 
percentage of cells in proliferation was assessed by counting 
Ki-67–positive nuclei number using a Cellomics Arrayscan 
automated microscope (Thermo Scientific, Hudson, NH).
Metforgene clinical trial for the INSR exon 11 splicing moni-
toring in diabetic patients. An interventional clinical trial was 
promoted by CERITD in the Centre Hospitalier Sud Francilien 
(Corbeil-Essonnes, France) (NCT 01349387) to investigate 
whether a treatment with metformin in patients with Type 2 
diabetes had an effect on INSR exon 11 alternative splicing 
of the insulin receptor. During their visit of consultation on the 
follow-up to the Type 2 diabetes, 15 patients were selected on 
the basis of active metformin treatment at a dose greater than 
or equal to 1,400 mg/day. After inclusion in the study to day 0, 
metformin treatment will be interrupted between day 1 and day 
30, replaced by Januvia 100 mg/day dose, and then resumed 
at day 31. Patients had to achieve a 10 ml blood sample at 
day 0, day 30, and 1 month after metformin retreatment. Blood 
samples were processed by Ficoll gradient centrifugation to 
isolate the circulating leukocytes. Total RNA was extracted 
using the RNeasy Micro/Mini kit (Qiagen) and reverse tran-
scribed using random hexamers and Superscript III Reverse 
Transcriptase kit (Invitrogen). Expressions of INSR +/− exon 11 
transcripts and 18S were monitored with TaqMan gene expres-
sion assays using the primers and MGB probes described in 
Supplementary Table S5 and TaqMan Gene Expression Mas-
ter Mix (Applied Biosystems) using the 7900HT Fast Real-Time 
PCR System (Applied Biosystems). The method described by 
Pfaffl60 was used to determine the relative expression level of 
each gene. FAS exon 6 alternative splicing was additionally 
tested by RT–PCR. PCR amplification was carried out with 
recombinant Taq DNA polymerase (Invitrogen) and the prim-
ers listed in Supplementary Table S5. The amplification was 
performed using a first step at 94 °C for 3 minutes followed by 
30 cycles of 45 seconds at 94 °C, 30 seconds at 55 °C, 30 sec-
onds at 72 °C, and finished with a final 10 minutes extension 
at 72 °C. The PCR products were quantified using the Bioana-
lyzer 2100 and DNA 1000 LabChip kit (Agilent). Statistics were 
computed using JMP9 software (SAS, Cary, NC). Statistical 
differences were determined with a Wilcoxon paired test. Dif-
ferences between groups were considered significant when P 
<0.05 (*P < 0.05; **P < 0.01; *** P < 0.001).
Statistical analysis. Statistics were computed in JMP using 
P values. Values are reported as mean and SD. Differences 
between groups were considered significant when P <0.05 
(*P < 0.05; **P < 0.01; ***P < 0.001). According the size of the 
experiment, samples parametric (ANOVA and post hoc tests) 
or nonparametric tests were chosen.
Supplementary Material
Figure S1. Western blot analysis of RBM3, SRSF1, SRSF6, 
RBM45 and SFPQ expressions in wild type or DM1 MPCs in 
response to metformin treatment.
Figure S2. Heatmap representation of the splicing events 
modulated by metformin in DM1 MPCs and analysis of RBM3 
RNA-binding protein involvement in this regulation.
Figure S3. Analysis of  RBM3 transcript variants that are 
candidate to the non sense mediated decay in response to 
metformin and cycloheximide treatments in DM1 MPCs.
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Figure S4. RT-PCR detection of 6 DM1 associated splicing 
defects in myoblasts from 2 non affected individuals or 2 DM1 
patients, treated with metformin, pentamidine or AICAR.
Figure S5. Metformin does not impact the alternative splic-
ing of 16 splicing defects in DM1 mutated myoblasts (DM16) 
treated for 48 hours with a range of dose of metformin.
Figure S6. Impact of pentamidine on RBM3 expression and 
DM1 associated splicing defects in DM1 human myoblasts.
Figure S7. In vitro evaluation of metformin and sitagliptin 
treatments on INSR exon 11 splicing in peripheral blood lym-
phocytes.
Table S1. List of genes modulated by 10mM metformin treat-
ment for 48 hours in DM1 MPCS.
Table S2. List of genes modulated by 25mM metformin treat-
ment for 48 hours in DM1 MPCS.
Table S3. List of splicing events modulated by 10 mM and 25 
mM metformin treatments for 48 hours in DM1 MPCS.
Table S4. Effect of 25 mM metformin, 75 µM pentamidine and 
2 mM AICAR on the regulation of alternative splicings altered 
in the DM1 mutated human myoblasts DM16.
Table S5. Human primers, probes and siRNA sequences.
Table S6. Detailed procedures of reverse transcription- 
quantitative PCR experiments according to the MIQE Guideli.
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